Drug Type Bispecific antibody |
Synonyms Anti-CD40/PDL1 Bispecific antibody(Lyvgen Biopharma Co., Ltd), LVGN-3036 |
Target |
Action agonists, inhibitors |
Mechanism CD40 agonists(Tumor necrosis factor receptor superfamily member 5 agonists), PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | China | - |






